Prevalence and risk factors for osteopenia/osteoporosis in an HIV-infected male population

Wiener Klinische Wochenschrift

Volumn 119, Issue 21-22, 2007, Pages 639-646

  Tomažič, Janez ^a   Ul, Katja ^a   Volčanšek, Gabriele ^a   Gorenšek, Samo ^a   Pfeifer, Miša ^a   Karner, Primož ^a   Preželj, Janez ^a   Vidmar, Gaj ^b   Vidmar, Ludvik ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Antiretroviral therapy; HIV; Osteopenia; Osteoporosis; Risk factors

Indexed keywords

ABACAVIR; ALCOHOL; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; CD4+ T LYMPHOCYTE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FAMILY HISTORY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIP FRACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OSTEOPENIA; OSTEOPOROSIS; PREVALENCE; RISK FACTOR; SCREENING; SMOKING; TREATMENT DURATION; VIRUS LOAD; VITAMIN D DEFICIENCY; WAIST HIP RATIO;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAUSALITY; COMORBIDITY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SLOVENIA;

EID: 36949018171     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-007-0844-x     Document Type: Article

References (37)

1. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, et al (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14: F63-F67
2. Mondy K, Tebas P (2003) Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis 36 [Suppl 2]: S101-S105
3. Moore AL, Vashisht A, Sabin CA, Mocroft A, Madge S, Philips AN, et al (2001) Reduced bone mineral density in HIV-positive individuals. AIDS 15: 1731-1733
4. Amiel C, Ostertag A, Slama L, Baudoin C, N'Guyen T, Lajeunie E, et al (2004) BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19: 402-409
5. Mangili A, Jacobson DL, Gerrior J, Polak JF, Gorbach SL, Wanke CA (2007) Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin Infect Dis 44: 1368-1374
6. Koch RO, Graziadei IW, Zangerle R, Romani N, Maier H, Vogel W (2003) Hepatic failure and lactate acidosis associated with antiretroviral treatment for HIV. Wien Klin Wochenschr 115: 135-140
7. Tomažic J, Silic A, Karner P, Vidmar L, Maticic M, Poljak M, et al (2004) Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients. Wien Klin Wochenschr 22: 755-759
8. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17: 1917-1923
9. Brown TT, Qaqish R (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: meta-analytic review. AIDS 20: 2165-2174
10. Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabo EV, Melzi S, et al (2006) Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 38: 893-897
11. Tebas P, Yarasheski K, Henry K, Claxton S, Kane E, Bordenave B, et al (2004) Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 20: 589-594
12. Kelepouris N, Harper KD, Gannon F, Kaplan FS, Haddad JG (1995) Severe osteoporosis in men. Ann Inter Med 123: 452-460
13. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36: 482-490
14. Mallon PW, Miller J, Cooper DA, Carr A (2003) Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 17: 971-979
15. Writing group for the ISCD position development conference (2004) Diagnosis of osteoporosis in men, premenopausal women, and children. J Clin Densitom 7: 17-26
16. Amorosa V, Tebas P (2006) Bone disease and HIV infection. Clin Infect Dis 42: 108-114
17. Bongiovanni M, Tincati C (2006) Bone diseases associated with human immunodeficiency virus infection: pathogenesis, risk factors and clinical management. Curr Mol Med 6: 395-400
18. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al (2004) Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. 903 Study Group. JAMA 2923: 191-201
19. Jacobson D, Huang J, Shevitz A, Knox T, Gorbach S, Spiegelman D (2005) Duration of ART and change in bone mineral density over time [abstract 825]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22-25
20. Fernandez-Rivera J, Garcia R, Lozano F, Macias J, Garcia-Garcia JA, Mira JA, et al (2003) Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 4: 337-346
21. Brown TT, McComsey GA (2006) Osteopenia and osteoporosis in patients with HIV: a review of current concepts. Curr Infect Dis Rep 8: 162-170
22. Annapoorna N, Venkateswara Rao G, Reddy NS, Rambabu P, Samabasiva Rao KRS (2004) An increased risk of osteoporosis during acquired immunodeficiency syndrome. Int J Med Sci 1: 152-164
23. Nolan D, Upton R, McKinnon E, John M, James I, Adler B, et al (2001) Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 15: 1275-1280
24. Powderly WG, Cohen C, Gallant JE (2005) Similar incidence of osteopenia and osteoporosis in ART-naïve patients treated with tenofovir DF or stavudine in combination with lamivudine or efavirenz over 144 weeks [abstract 823]. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22-25
25. Aukrust P, Haug CJ, Ueland T, Lien E, Muller F, Espevik T, et al (1999) Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 84: 145-150
26. Teichmann J, Stephan E, Lange U, Discher T, Friese G, Lohmeyer J, et al (2003) Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect 46: 221-227
27. Clerici M, Trabattoni D, Piconi S, Fusi ML, Ruzzante S, Clerici C, et al (1997) A possible role for the cortisol/ anticortisols imbalance in the progression of human immunodeficiency virus. Psychoneuroendocrinology 22 [Suppl 1]: S27-S31
28. Frost RA, Fuhrer J, Steigbigel R, Mariuz P, Lang CH, Gelato MC (1996) Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. Clin Endocrinol 44: 501-514
29. Dube MP, Qian D, Edmondson-Melancon H, Sattler FR, Goodwin D, Martinez C, et al (2002) Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 35: 475-481
30. Vescini F, Borderi M, Buffa A, Sinicropi G, Tampellini L, Chiodo F (2003) Bone mass in HIV-infected patients: focus on the role of therapy and sex. J Acquir Immune Defic Syndr 33: 405-412
31. Bongiovanni M, Fausto A, Cicconi P, Aliprandi A, Cornalba G, Bini T, et al (2006) Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects. J Antimicrob Chemother 58: 485-486
32. Seminari E, Castagna A, Soldarini A, Galli L, Fusetti G, Dorigatti F, et al (2005) Osteoprotegrin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med 6: 145-150
33. Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, et al (2004) Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 48: 39-48
34. Negredo E, Martínez E, Cinquegrana D, Estany C, Clotet B (2007) Therapeutic management of bone demineralization in the HIV-infected population. AIDS 21: 657-663.
35. Kanis JA, Johnell O, Oden A, De Laet C, de Terlizzi F (2005) Ten-year probabilities of clinical vertebral fractures according to phalangeal quantitative ultrasonography. Osteoporos Int 16: 1065-1070
36. McComsey GA, Huang JS, Woolley IJ, Young B, Sax PE, Gerber M, et al (2004) Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. J Int Assoc Physicians AIDS Care 3: 86-91
37. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Yungtai Lo, Klein RS (2007) Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 21: 617-623